10-K: Royalty Pharma's 2025 Performance: Strong Growth, Strategic Internalization

Royalty Pharma reports robust 16.2% growth in Portfolio Receipts to $3.3 billion in 2025, driven by strategic acquisitions and product performance, despite a dip in net income attributable to shareholders.

Summary

• Portfolio Receipts increased by 16.2% to $3.254 billion in 2025, up from $2.801 billion in 2024.
• Capital Deployment for royalty acquisitions, milestones, and other contractual receipts totaled $2.6 billion in 2025.
• Net income attributable to Royalty Pharma plc decreased by 10.2% to $770.9 million in 2025, compared to $859.0 million in 2024.
• General and administrative expenses surged by 142.3% to $573.5 million in 2025, primarily due to the internalization of the manager and associated share-based compensation.
• Interest expense increased by 36.4% to $307.7 million in 2025, driven by new senior unsecured notes issuances.
• The company repurchased $1.2 billion of Class A ordinary shares in 2025, with $1.8 billion remaining under the new $3.0 billion repurchase program.
• Key acquisitions in 2025 included royalty interests in Alnylam's Amvuttra ($310 million), Amgen's Imdelltra ($885 million upfront, plus $26 million additional), Nuvalent's neladalkib and zidesamtinib (up to $315 million), and remaining royalties on Roche's Evrysdi ($240 million upfront, up to $60 million in milestones).
• Significant funding arrangements include a two-part $2 billion deal with Revolution Medicines for daraxonrasib and a senior secured term loan, and an R&D funding arrangement with Biogen for litifilimab (up to $250 million).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report. Strong operational cash flow and strategic acquisitions underscore the company's market leadership and growth strategy, but the significant increase in G&A and interest expenses, coupled with a decline in net income attributable to shareholders, introduces some near-term headwinds and volatility.

Positives

• Portfolio Receipts grew significantly by 16.2% to $3.254 billion in 2025, demonstrating strong cash generation from portfolio investments.
• Capital Deployment for new royalty acquisitions remained robust at $2.6 billion in 2025, indicating continued execution of the growth strategy.
• The company completed the internalization of its former external manager, RP Management, LLC, in May 2025, aiming for enhanced alignment with shareholders and potential cash savings in the long term.
• A new $3.0 billion share repurchase program was authorized in January 2025, with $1.2 billion of shares repurchased during the year, signaling confidence in valuation and commitment to shareholder returns.
• Several key products in the portfolio showed strong growth in royalty receipts, including Cystic fibrosis franchise (+7.0%), Trelegy (+17.2%), Evrysdi (+16.2%), Xtandi (+16.7%), and Tremfya (+27.8%).
• New royalty acquisitions on approved products like Alnylam's Amvuttra and Amgen's Imdelltra (which received full FDA approval in November 2025) are expected to drive future cash flows.
• Development-stage product candidates like Myqorzo (aficamten) received FDA approval in December 2025, and Airsupra received supplemental FDA approval, validating investment in early-stage assets.
• The estimated weighted average duration of the portfolio is approximately 13 years, with key growth-driving royalties protected by long patent lives, such as Trikafta through 2037.

Negatives

• Net income attributable to Royalty Pharma plc decreased by 10.2% to $770.9 million in 2025, compared to $859.0 million in 2024.
• General and administrative expenses increased substantially by 142.3% to $573.5 million in 2025, largely due to share-based compensation and acquisition-related costs from the internalization.
• Interest expense rose by 36.4% to $307.7 million in 2025, reflecting increased indebtedness.
• Royalty receipts from Tysabri, Imbruvica, and Promacta decreased in 2025 due to increased competition, Medicare Part D redesign, and generic entry (Promacta).
• An ongoing dispute with Vertex regarding Alyftrek royalty receipts, where the company believes the deuterated ivacaftor component is royalty-bearing while Vertex does not, could impact future income.
• The company recorded provision expense related to Evrysdi due to declines in sell-side equity research analysts' consensus sales forecasts.

Risks

• Sales of biopharmaceutical products on which royalties are received may be lower than expected due to pricing pressures, insufficient demand, product competition, clinical trial failures, regulatory delays, lack of market acceptance, or loss of patent protection.
• The royalty market may not grow at the same rate as in the past, or at all, potentially limiting opportunities to acquire sufficient royalties to sustain business growth.
• Acquisitions of royalties from development-stage biopharmaceutical product candidates are subject to additional uncertainties, including failure to receive marketing approval, lower-than-expected pricing or reimbursement, or commercial failure.
• Strategic acquisitions of operating biopharmaceutical companies or securities of biopharmaceutical companies may not realize expected benefits and could expose the company to new liabilities or operational complexities.
• The use of leverage in capital deployment magnifies the potential for loss if acquired royalties do not generate sufficient income, and increased interest expense could reduce cash available for dividends or share repurchases.
• The success of the business depends on key members of the team, and their departure or competing demands on their time could adversely affect operations.
• The company requires significant cash to service indebtedness and meet liquidity needs, and its ability to generate cash depends on factors beyond its control.
• The business is subject to interest rate, foreign exchange, inflation, and banking industry risks, which can impact revenues, costs, and financial guidance.
• Information available about underlying biopharmaceutical products may be limited, leading to inaccurate cash flow estimates.
• Future income is dependent upon numerous royalty-specific assumptions (e.g., product sales, patent expirations, competition) which, if inaccurate, could lead to reduced returns or permanent impairment.
• Most royalties are classified as financial assets measured at amortized cost using the effective interest method, which can lead to volatile and unpredictable GAAP results due to non-cash charges.
• Reliance on a limited number of products (top five accounted for 61% of Royalty Receipts in 2025) exposes the company to concentration risk.
• Competition in acquiring royalties is significant and may increase, potentially limiting suitable opportunities or increasing acquisition costs.
• Biopharmaceutical products are subject to substantial competition, which could render products obsolete or non-competitive.
• Marketers of products generating royalties are outside of the company's control, and their strategic decisions or operational failures could adversely affect royalty payments.
• License agreements may be unilaterally terminated or disputes may arise, affecting royalty payments.
• The insolvency of a marketer could delay or impede royalty payments.
• Unsuccessful attempts to acquire new royalties could result in significant costs and divert management attention.
• Products generating royalties are subject to uncertainty related to healthcare reimbursement policies, pricing pressures, and government regulation (e.g., Inflation Reduction Act, MFN pricing).
• Sales of products are subject to regulatory approvals and actions in the U.S. and foreign jurisdictions, which could harm the business.
• Manufacture and distribution of biopharmaceutical products may be interrupted by regulatory agencies or supplier deficiencies.
• Product liability claims may diminish returns on biopharmaceutical products.
• The company is typically not involved in maintaining, enforcing, and defending patent rights on products that generate royalties, relying on partners to do so.
• Existence of third-party patents may result in additional costs for marketers and reduce royalty payments.
• Disclosure of trade secrets of marketers could negatively affect competitive position.
• The board of directors may decide not to pay dividends or repurchase shares, even if income is positive.
• Acquired assets may fall outside the biopharmaceutical industry and may not resemble the current portfolio's cash flows or returns.
• The organizational structure as a holding company relies on cash generated by subsidiaries, which may be subject to restrictions.
• The structure results in tax distributions due to RP Holdings Class C Special Interest, reducing cash available for reinvestment or shareholder returns.
• Ability to pay dividends or make share repurchases is limited by English law and contractual restrictions.
• If determined to be an investment company under the U.S. Investment Company Act of 1940, applicable restrictions could make it impractical to continue business as contemplated.
• Equity Performance Awards may create incentives not fully aligned with shareholder interests, potentially leading to riskier asset acquisitions.
• Operational risks, including cybersecurity vulnerabilities, failures in information systems, or risks associated with artificial intelligence, could disrupt business operations.
• Subject to the U.K. Bribery Act, U.S. Foreign Corrupt Practices Act, and other anti-corruption laws, as well as export control and trade sanctions laws, non-compliance could lead to penalties.
• Compliance with healthcare laws and regulations involves substantial costs and risk of non-compliance.
• The EU AIFM Directive may increase compliance costs and impact ability to attract investors in AIFM states.
• Failure to realize anticipated benefits of the Internalization or exposure to new risks and costs post-internalization.
• Volatility of the market price of Class A ordinary shares due to various factors.
• Articles of Association provide exclusive forum provisions, potentially limiting shareholder ability to bring claims.
• U.S. investors may have difficulty enforcing civil liabilities against the company or its management due to English law incorporation.
• Rights of shareholders may differ from those of a U.S. corporation, and certain capital structure decisions require shareholder approval.
• If Class A ordinary shares are not eligible for continued deposit and clearing within DTC facilities, transactions may be disrupted.
• Complex tax law provisions, potential legislative/judicial changes, and differing interpretations could lead to significant tax liabilities.
• Changes in eligibility for income tax treaty benefits or challenges to tax positions could result in increased withholding taxes.
• If subsidiaries are considered engaged in a U.S. trade or business, the company could be liable for significant U.S. taxation.
• Changes to management/organizational structure or tax residency laws could cause the company or RP Holdings to be treated as resident in another jurisdiction for tax purposes.
• Uncertainty regarding the application of U.K.'s controlled foreign companies rules and dividend tax exemptions.
• Classification as a PFIC for U.S. federal income tax purposes could subject U.S. holders to adverse tax consequences.
• The outbreak of infectious or contagious diseases could adversely affect results of operations, financial condition, and cash flows.
• Legal claims and proceedings, such as the dispute with Vertex, could require significant time and expense and divert management attention.
• Corporate responsibility matters and related reporting obligations may impact the business, increasing compliance costs and reputational risk.

Future Outlook

The company intends to continue growing its business by partnering with innovators across the biopharmaceutical value chain to fund innovation, seeking renewal of shareholder authorization for share allotment and share repurchase programs annually. It expects to fund current and planned operating costs primarily through cash flow from operations and investments through cash flow and issuances of equity and debt. The company also anticipates the Teva TEV-408 Phase 2b study for vitiligo to start in 2026, with an option for additional funding for Phase 3 development based on future results.

Management Comments

• We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry.
• We strive to be the premier capital allocator in life sciences with consistent, compounding growth.
• Our highly selective investment approach focuses on identifying and tracking important new therapies, which allows us to act efficiently when opportunities arise.
• Our simple and efficient operating model generates substantial cash flow to allocate in the best interest of our shareholders.
• We believe that our existing capital resources, cash provided by operating activities and access to our Revolving Credit Facility will continue to allow us to meet our operating and working capital requirements, to fund planned strategic acquisitions and R&D funding arrangements, and to meet our debt service obligations for the foreseeable future.
• We believe that the deuterated ivacaftor component of Alyftrek is the same as ivacaftor and is therefore royalty-bearing, despite Vertex's public statements to the contrary.

Industry Context

StockSavvy.ai notes Royalty Pharma's strong market leadership, having executed an estimated 48% of all royalty transactions from 2020-2025, and 69% of large transactions ($500M+). This positions the company to capitalize on the projected growth of global prescription pharmaceutical sales from $1.2 trillion in 2025 to $2.0 trillion in 2032 (7% CAGR), driven by population growth, increased life expectancy, and R&D investments. The increasing cost and complexity of drug development continue to create significant capital needs, fostering a sustainable tailwind for the biopharmaceutical royalty market, which reached $10.0 billion in transaction value in 2025, a 40% increase over the prior five-year average.

Comparison to Industry Standards

• Royalty Pharma's estimated market share of approximately 48% of all royalty transactions from 2020 through 2025 significantly outperforms its nearest competitor, which executed an estimated 14% of transactions over the same period ($19.4 billion vs. $5.5 billion).
• The company's success rate for development-stage acquisitions, with products underlying $6.5 billion of these acquisitions already approved (90% success rate to date), demonstrates strong due diligence and investment selection compared to typical early-stage R&D risks in the broader biopharmaceutical industry.
• The portfolio's diversification across over 35 marketed therapies and 20 development-stage candidates, with no single product accounting for more than 26% of Portfolio Receipts in 2025, provides a more stable revenue stream compared to many single-product focused biopharmaceutical companies.
• The estimated weighted average duration of the portfolio at approximately 13 years, with key growth-driving royalties like Trikafta protected through 2037, indicates a long-term cash flow profile that is attractive relative to shorter-duration assets common in the industry.

Management Changes

Corporate Governance

Legal Proceedings

• Beginning in the second quarter of 2025, the company did not receive the full amount of royalty receipts on Alyftrek net sales from Vertex, to which it believes it is contractually entitled. Dispute resolution procedures have commenced.

Related Party Transactions

• The Internalization of RP Manager on May 16, 2025, involved Pablo Legorreta (CEO and Chairman) and other named executive officers as sellers, receiving cash and equity consideration.
• Prior to the Internalization, the company paid Management Fees to RPM (Legacy Manager), which was managed by Pablo Legorreta. These fees ceased post-Internalization.
• After the Internalization, the company entered into an agreement with RPM to provide administrative services in exchange for a fee.
• Christopher Hite, Executive Vice President & Vice Chairman, serves as a director of Kailera Therapeutics Inc., from which the company acquired preferred stock in October 2025.
• Errol De Souza, an independent director, was a shareholder of Psyadon Pharmaceuticals, Inc., from which the company acquired a royalty interest in ecopipam in January 2024, resulting in payments to Dr. De Souza.
• The company holds a special limited partnership interest (Legacy SLP Interest) in the Legacy Investors Partnerships, which entitles it to performance distribution payments and income allocation.
• RPIFT owns limited partnership interests in the Continuing Investors Partnerships, whose operations primarily involve investment in the company's subsidiaries.

Stakeholder Impact

• Shareholders: Potential for increased long-term value through strategic acquisitions and share repurchases, but near-term net income decline and increased expenses may impact profitability. The ongoing dispute with Vertex could affect future royalty receipts.
• Employees: Internalization led to former manager employees becoming company employees, potentially improving alignment and continuity. Share-based compensation plans are in place.
• Partners (Innovators/Biopharmaceutical Companies): Royalty Pharma continues to be a leading funder of innovation, providing non-dilutive capital through various structures, which supports R&D and commercialization efforts across the industry.
• Customers (Patients): The company's investments in biopharmaceutical royalties support the development and commercialization of therapies addressing significant unmet patient needs across various therapeutic areas.
• Creditors: Increased indebtedness and interest expense, but the company remains in compliance with debt covenants and has access to substantial capital markets, indicating continued ability to meet obligations.

Next Steps

• Seek renewal of shareholder authorization to allot and issue new Class A ordinary shares at each year's annual general meeting.
• Seek renewal of shareholder authorization to disapply preemptive rights at each year's annual general meeting.
• Seek renewal of shareholder approval for off-market share repurchases upon expiration (five years from May 12, 2025).
• Teva Pharmaceuticals' TEV-408 Phase 2b study for vitiligo targeted to start in 2026, with an option for additional Phase 3 funding.
• Pharvaris expects to file marketing authorization applications for deucrictibant in H1 2026.
• Zenas BioPharma anticipates submitting a Biologics License Application for obexelimab in Q2 2026 and a Marketing Authorization Application to the EMA in H2 2026.
• Novartis plans to submit an EU regulatory filing for pelabresib in 2026 and initiate a new Phase 3 study in the U.S., Canada, and Japan.
• Roche initiated the Phase 3 program for trontinemab in early symptomatic Alzheimer's disease and plans to initiate a Phase 3 study in preclinical Alzheimer's disease.

Key Dates

Recommendation

Royalty Pharma demonstrates strong operational execution with significant growth in Portfolio Receipts and continued strategic capital deployment into new royalty assets. The internalization of its manager is a positive long-term move for alignment and efficiency. However, the notable increase in G&A and interest expenses, leading to a decrease in net income attributable to shareholders, introduces near-term financial pressure. The ongoing dispute with Vertex also presents an unresolved risk. While the long-term outlook remains favorable due to the company's unique business model and market position, these factors suggest a 'hold' recommendation for seasoned investors, allowing time for the benefits of the internalization to materialize and for the resolution of current challenges.

Keywords

Biopharmaceutical royalties, Royalty acquisition, Life sciences investment, SEC filing, RPRX, Pharmaceutical industry, Drug development funding, Portfolio receipts, Capital deployment, Financial assets, Corporate governance, Risk management, Share repurchase, Internalization, Cystic fibrosis, Oncology, Rare disease, Neuroscience, Immunology, Patent protection